SNMMI Defines Training Standards for Rapidly Expanding Radiopharmaceutical Therapy Field

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a position paper detailing the education, training, and experience required to safely and effectively deliver radiopharmaceutical therapy (RPT)—a fast-growing form of precision cancer treatment. The paper, published in The Journal of Nuclear Medicine in October, underscores SNMMI’s leadership in setting global standards for this transformative field.

Radiopharmaceutical therapies use targeted radioactive compounds to treat disease and are reshaping cancer care. Pharmaceutical companies have invested billions in developing new theranostic and combination treatments, including Pluvicto and Lutathera (Novartis), Xofigo (Bayer), and Azedra (Lantheus). As demand rises, the need for trained professionals and additional treatment centers is expected to grow substantially.

Although RPT has been part of nuclear medicine for nearly a century, interest is now expanding beyond the specialty. The paper warns that safe delivery requires specialized expertise in radiation safety, dosimetry, and patient management—skills gained through years of focused training. Administering these therapies without proper credentials, it cautions, could jeopardize patient safety.

“Radiopharmaceutical therapy represents one of the most promising frontiers in cancer care,” the authors wrote. “As its use grows, it’s vital that delivery remain in the hands of appropriately trained professionals to ensure safety, efficacy, and quality.”

To meet growing demand, SNMMI has expanded training programs, established Centers of Excellence, provided accreditation, and developed treatment protocols and clinical trial guidance. It also offers ongoing professional development for physicians, technologists, radiochemists, radiopharmacists, physicists, and other specialists.

The paper stresses strict adherence to safety protocols, precise dosimetry, and robust radiation safety practices—critical for protecting patients and ensuring effective therapy. SNMMI also highlights its global collaborations to harmonize guidelines and promote consistent, high-quality care worldwide.

“The field of nuclear medicine is poised to drive the clinical implementation and global expansion of theranostics,” the authors concluded. “Through interdisciplinary and multidisciplinary collaboration, nuclear medicine professionals can advance the field, innovate productively, and share best practices worldwide.”